24.77USD+5.72%Mkt Cap: 3.10B USDP/E: —Last update: 2026-05-26
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap3.10B USD
Enterprise Value2.29B USD
Revenue (TTM)236.00M USD
Gross Profit-287.00M USD
Net Income (TTM)-353.00M USD
Revenue/Share2.067 USD
Last Price24.77 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees601
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.64
PEG—
EV/EBITDA-5.89
EV/Revenue9.72
P/S12.72
P/B5.72
EPS (TTM)-3.17
EPS (Forward)-3.12
52W Range
7.91081% of range28.72
52W High28.72 USD
52W Low7.910 USD
Profitability
Gross Margin-121.61%
Oper. Margin-788.24%
EBITDA Margin-164.83%
Profit Margin-142.91%
ROE-55.94%
ROA-30.99%
Growth
Revenue Growth-39.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-482.00M USD
CapEx (TTM)2.00M USD
FCF Margin-66.10%
FCF Yield-5.03%
Net Debt-709.00M USD
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.18
Current Ratio4.04
Quick Ratio3.97
Book Value/Sh4.175 USD
Cash/Share6.536 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)34.82 USD
Target Range22.00 USD – 47.00 USD
# Analysts11
Ownership
Shares Out.125.77M
Float89.09M
Insiders29.13%
Institutions72.59%
Short Interest
Short Ratio8.4d
Short % Float14.23%
Short % Out.8.65%
Shares Short10.88M
Short (prev mo.)9.88M
Technical
SMA 5023.44 (+5.7%)
SMA 20019.63 (+26.2%)
Beta0.87
S&P 52W Chg28.31%
Avg Vol (30d)1.16M
Avg Vol (10d)768.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—